MedTrace Logo

The Healthcare Evaluation of Absolute Risk Testing Study

NCT05294419 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 862

Last updated 2025-12-08

Study results available
· View outcomes & findings →

Summary

The aim of this study is to demonstrate the integration and use of cardiovascular disease (CVD) integrated risk tool (IRT) in an environment as close to real-world as possible.

This study will recruit participants of both biological sexes and any ancestry or background who require and are eligible for a CVD risk assessment as part of the NHS Health Check. Those aged 45-64 years are most likely to benefit from CVD IRT and will be included in the study, as they are more likely to be asymptomatic but also derive most benefit from preventative measures.

The study will be conducted in GP surgeries as the CVD IRT will have its greatest impact if incorporated into primary care practice for early identification of patients at highest risk.

This study is a device performance evaluation.

Conditions

Interventions

DEVICE

CVD Integrated Risk Test

CVD IRT (Cardiovascular Integrated Risk Tool)

Sponsors & Collaborators

  • NHS North of England Commissioning Support (NECS)

    collaborator UNKNOWN

  • Genomics PLC

    lead INDUSTRY

Principal Investigators

  • A Fuat, Prof · Carmel Medical Practice

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-04
Primary Completion
2022-08-31
Completion
2022-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05294419 on ClinicalTrials.gov